SLC12A2 and Alzheimer disease: Although bumetanide, a known NKCC1 inhibitor, has demonstrated neuroprotective effects, its clinical utility in AD remains limited due to poor brain penetration and systemic side effects (Glykys et al., 2014; Töllner et al., 2014).